German federal-state-wide seroprevalence study of 1
Population screening
Viral infection
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
05
2021
accepted:
09
03
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Reliable data on the adult SARS-CoV-2 infection fatality rate in Germany are still scarce. We performed a federal state-wide cross-sectional seroprevalence study named SaarCoPS, that is representative for the adult population including elderly individuals and nursing home residents in the Saarland. Serum was collected from 2940 adults via stationary or mobile teams during the 1 Using a highly specific total antibody test detecting anti-SARS-CoV-2 responses over more than 180 days, we estimate an adult infection rate of 1.02% (95% CI: [0.64; 1.44]), an underreporting rate of 2.68-fold (95% CI: [1.68; 3.79]) and infection fatality rates of 2.09% (95% CI: (1.48; 3.32]) or 0.36% (95% CI: [0.25; 0.59]) in all adults including elderly individuals, or adults younger than 70 years, respectively. The study highlights the importance of study design and test performance for seroprevalence studies, particularly when seroprevalences are low. Our results provide a valuable baseline for evaluation of future pandemic dynamics and impact of public health measures on virus spread and human health in comparison to neighbouring countries such as Luxembourg or France.
Sections du résumé
Background
UNASSIGNED
Reliable data on the adult SARS-CoV-2 infection fatality rate in Germany are still scarce. We performed a federal state-wide cross-sectional seroprevalence study named SaarCoPS, that is representative for the adult population including elderly individuals and nursing home residents in the Saarland.
Methods
UNASSIGNED
Serum was collected from 2940 adults via stationary or mobile teams during the 1
Results
UNASSIGNED
Using a highly specific total antibody test detecting anti-SARS-CoV-2 responses over more than 180 days, we estimate an adult infection rate of 1.02% (95% CI: [0.64; 1.44]), an underreporting rate of 2.68-fold (95% CI: [1.68; 3.79]) and infection fatality rates of 2.09% (95% CI: (1.48; 3.32]) or 0.36% (95% CI: [0.25; 0.59]) in all adults including elderly individuals, or adults younger than 70 years, respectively.
Conclusion
UNASSIGNED
The study highlights the importance of study design and test performance for seroprevalence studies, particularly when seroprevalences are low. Our results provide a valuable baseline for evaluation of future pandemic dynamics and impact of public health measures on virus spread and human health in comparison to neighbouring countries such as Luxembourg or France.
Identifiants
pubmed: 35603305
doi: 10.1038/s43856-022-00100-z
pii: 100
pmc: PMC9117207
doi:
Types de publication
Journal Article
Langues
eng
Pagination
52Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Int J Environ Res Public Health. 2021 Mar 30;18(7):
pubmed: 33808249
Lancet Infect Dis. 2021 Feb;21(2):203-212
pubmed: 33091374
J Clin Virol. 2022 Jan;146:105052
pubmed: 34920374
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Biotechnol. 2020 Oct;38(10):1174-1183
pubmed: 32855547
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
JAMA Netw Open. 2021 Mar 1;4(3):e210417
pubmed: 33666657
Clin Infect Dis. 2021 Jan 27;72(2):249-253
pubmed: 33501969
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700672
Nat Commun. 2021 Feb 19;12(1):1152
pubmed: 33608538
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Am J Epidemiol. 1978 Jan;107(1):71-6
pubmed: 623091
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243353
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Lancet Infect Dis. 2020 Nov;20(11):1231-1232
pubmed: 32530425
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Stat Med. 1994 May 30;13(10):1071-82
pubmed: 8073202
J Health Monit. 2020 Nov 13;5(Suppl 4):2-15
pubmed: 35146294
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Immunity. 2021 Feb 9;54(2):340-354.e6
pubmed: 33567252
Viruses. 2021 Jun 10;13(6):
pubmed: 34200766
Epidemiol Infect. 2020 Jun 29;148:e130
pubmed: 32594937
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
J Virol Methods. 2021 Oct;296:114222
pubmed: 34197839